精神分裂症或心境障碍患者迟发性运动障碍药物干预的疗效与可接受性:系统综述与网络荟萃分析
该系统综述与网络荟萃分析纳入46项随机对照试验(n=2844),评估药物干预对多巴胺受体拮抗剂所致迟发性运动障碍的疗效与可接受性。仅valbenazine和维生素E在限定高质量试验中优于安慰剂,deutetrabenazine在低偏倚风险试验中优于安慰剂;换用molindone和抗精神病药洗脱应避免。
要点
- 在仅纳入样本量>20且试验数>1的试验中,valbenazine(SMD=-0.69)和维生素E(SMD=-0.49)优于安慰剂。
- Deutetrabenazine在低偏倚风险试验中优于安慰剂,24/36 mg的SMD为-0.57/-0.60。
- 换用molindone较换用氟哌啶醇加重迟发性运动障碍(SMD=1.68),抗精神病药洗脱+安慰剂较常规治疗+安慰剂加重症状(SMD=1.30)。
核心结论
- 尽管部分治疗效应量大但证据质量/置信度极低,仅考虑较高质量证据时,valbenazine或deutetrabenazine是迟发性运动障碍的循证一线治疗,维生素E可能为二线。
- 换用molindone和抗精神病药洗脱应避免。
- 需要更多治疗选择和更高质量的试验。
研究设计与样本
- 系统综述与随机效应网络荟萃分析,检索PubMed/MEDLINE/PsycINFO/ClinicalTrials.gov/Cochrane Central Register(截至2023年5月22日),预设方案见https://osf.io/b52ae/。
- 纳入46项随机对照试验,共2844例成人精神分裂症或心境障碍患者(年龄52.89±9.94岁,男性59.8%,精神分裂症84.6%,心境障碍15.4%),所有试验均比较药物干预与安慰剂。
主要发现
- 网络1(k=34,n=2269)中,22种干预与安慰剂比较,多种治疗在迟发性运动障碍症状上优于安慰剂且效应量大,但18种仅有1项随机对照试验,15种样本量≤20;异质性高(I²=57.1%;tau²=0.0797),全局不一致性显著(Q=32.64;df=14;p=0.0032);可接受性无显著差异。
- 限制为样本量>20且试验数>1的分析中,仅valbenazine(k=5,SMD=-0.69;95%CI=-1.00,-0.37)和维生素E(k=7,SMD=-0.49;95%CI=-0.87,-0.11)优于安慰剂。
- Deutetrabenazine在考虑AIMS评分及仅低偏倚风险试验中优于安慰剂,24/36 mg的效应量中等(k=2,SMD=-0.57/-0.60)。
- 网络2(k=2,n=63)中,换用molindone(k=1,n=9)较换用氟哌啶醇加重迟发性运动障碍(SMD=1.68;95%CI=0.61,2.76)。
- 网络3(k=3,n=194)中,抗精神病药洗脱+安慰剂(k=1,n=25)较常规治疗+安慰剂(k=1,n=27)加重迟发性运动障碍(SMD=1.30;95%CI=0.36,2.23)。
关键数值与推荐
- 主要结局为迟发性运动障碍症状变化(标准化均数差/SMD)和全因停药(可接受性-风险比/RR)。
- Valbenazine(k=5)SMD=-0.69(95%CI=-1.00,-0.37);维生素E(k=7)SMD=-0.49(95%CI=-0.87,-0.11);deutetrabenazine 24/36 mg(k=2)SMD=-0.57/-0.60。
- 换用molindone较换用氟哌啶醇SMD=1.68(95%CI=0.61,2.76);抗精神病药洗脱+安慰剂较常规治疗+安慰剂SMD=1.30(95%CI=0.36,2.23)。
- 对deutetrabenazine和valbenazine的证据置信度为低,对其他所有干预为极低。
临床怎么用
- 作者认为,仅考虑较高质量证据时,valbenazine或deutetrabenazine是迟发性运动障碍的循证一线治疗,维生素E可能为二线。
- 作者认为,换用molindone和抗精神病药洗脱应避免。
局限性
- 18种干预仅有1项随机对照试验,15种样本量≤20。
- 异质性高(I²=57.1%;tau²=0.0797),全局不一致性显著(Q=32.64;df=14;p=0.0032)。
- 对deutetrabenazine和valbenazine的证据置信度为低,对其他所有干预为极低。
- 需要更多治疗选择和更高质量的试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Tardive Dyskinesia (TD) can occur in people exposed to dopamine receptor antagonists (DRAs). Its clinical management remains challenging. We conducted a systematic review/random-effects network meta-analysis (NMA) searching PubMed/MEDLINE/PsycINFO/ClinicalTrials.gov/Cochrane Central Register (22/05/2023, pre-defined protocol https://osf.io/b52ae/ ), for randomized controlled trials (RCTs) of pharmacological/brain stimulation interventions for DRA-induced TD in adults with schizophrenia or mood disorders. Primary outcomes were TD symptom change (standardized mean difference/SMD) and all-cause discontinuation (acceptability-risk ratio/RR). Sensitivity analyses were conducted. Global, local inconsistencies, risk of bias (RoB-2 tool), and confidence in evidence (CINeMA) were measured. We included 46 trials (n = 2844, age = 52.89 ± 9.94 years, males = 59.8%, schizophrenia = 84.6%, mood disorders = 15.4%), all testing pharmacological interventions versus placebo. We identified three subnetworks. In network 1, several treatments outperformed placebo on TD symptoms with large effect sizes (k = 34, n = 2269), encompassing 22 interventions versus placebo, but 18 had 1 RCTs only, and 15 had n ≤ 20. High heterogeneity (I2 = 57.1%; tau2 = 0.0797), and global inconsistency (Q = 32.64; df = 14; p = 0.0032) emerged. No significant differences emerged in acceptability. When restricting analyses to treatments with trials with n > 20 and >1 RCT, only valbenazine (k = 5, SMD = -0.69; 95% CI = -1.00, -0.37) and vitamin E (k = 7, SMD = -0.49; 95% CI = -0.87, -0.11) were superior to placebo. Deutetrabenazine outperformed placebo considering AIMS score and in low risk of bias trials only and with a moderate effect size for 24/36 mg (k = 2, SMD = -0.57/-0.60). Confidence in findings was low for deutetrabenazine and valbenazine, very low for all others. In network 2 (k = 2, n = 63), switch to molindone (k = 1, n = 9) versus switch to haloperidol worsened TD (SMD = 1.68; 95% CI = 0.61,2.76). In network 3 (k = 3, n = 194), antipsychotic wash-out+placebo (k = 1, n = 25) versus TAU+placebo (k = 1, n = 27) worsened TD (SMD = 1.30; 95% CI = 0.36,2.23). Despite large effect sizes for some treatments with very low quality/confidence, when considering higher quality evidence only valbenazine or deutetrabenazine are evidence-based first-line treatments for TD, and potentially vitamin E as second-line. Switching to molindone and antipsychotic washout should be avoided. More treatment options and higher-quality trials are needed.
引用
- Solmi M, Fornaro M, Caiolo S, et al. Efficacy and acceptability of pharmacological interventions for tardive dyskinesia in people with schizophrenia or mood disorders: a systematic review and network meta-analysis. Mol Psychiatry. 2024. PMID: 39695322. doi:10.1038/s41380-024-02733-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。